+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Hypoparathyroidism - Pipeline Review, H2 2019

  • ID: 4901315
  • Drug Pipelines
  • December 2019
  • Region: Global
  • 64 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Aerami Therapeutics
  • Alize Pharma III SAS
  • Ascendis Pharma A/S
  • Eli Lilly and Co
  • Entera Bio Ltd
  • Extend Biosciences Inc
  • MORE
Hypoparathyroidism - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Hypoparathyroidism - Pipeline Review, H2 2019, provides an overview of the Hypoparathyroidism (Hormonal Disorders) pipeline landscape.

Hypoparathyroidism is decreased function of the parathyroid glands with underproduction of parathyroid hormone. This leads to low levels of calcium in the blood, often causing cramping and twitching of muscles (involuntary muscle contraction), and several other symptoms. The condition can be inherited, but it is also encountered after thyroid or parathyroid gland surgery, and it can be caused by immune system-related damage as well as a number of rarer causes. The treatment includes artificial form of the hormone that can be administered as replacement, calcium replacement or vitamin.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Hypoparathyroidism - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Hypoparathyroidism (Hormonal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hypoparathyroidism (Hormonal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hypoparathyroidism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 5 and 3 respectively.

Hypoparathyroidism (Hormonal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hypoparathyroidism (Hormonal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Hypoparathyroidism (Hormonal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hypoparathyroidism (Hormonal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hypoparathyroidism (Hormonal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hypoparathyroidism (Hormonal Disorders)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hypoparathyroidism (Hormonal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hypoparathyroidism (Hormonal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Aerami Therapeutics
  • Alize Pharma III SAS
  • Ascendis Pharma A/S
  • Eli Lilly and Co
  • Entera Bio Ltd
  • Extend Biosciences Inc
  • MORE
Introduction
Report Coverage
Hypoparathyroidism - Overview
Hypoparathyroidism - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Hypoparathyroidism - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hypoparathyroidism - Companies Involved in Therapeutics Development
Aerami Therapeutics
Alize Pharma III SAS
Ascendis Pharma A/S
Chugai Pharmaceutical Co Ltd
Eli Lilly and Co
Entera Bio Ltd
Extend Biosciences Inc
GC Pharma
Sigilon Therapeutics Inc
Takeda Pharmaceutical Co Ltd
Hypoparathyroidism - Drug Profiles
Hypoparathyroidism - Dormant Projects
Hypoparathyroidism - Discontinued Products
Hypoparathyroidism - Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Hypoparathyroidism, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Hypoparathyroidism - Pipeline by Aerami Therapeutics, H2 2019
Hypoparathyroidism - Pipeline by Alize Pharma III SAS, H2 2019
Hypoparathyroidism - Pipeline by Ascendis Pharma A/S, H2 2019
Hypoparathyroidism - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2019
Hypoparathyroidism - Pipeline by Eli Lilly and Co, H2 2019
Hypoparathyroidism - Pipeline by Entera Bio Ltd, H2 2019
Hypoparathyroidism - Pipeline by Extend Biosciences Inc, H2 2019
Hypoparathyroidism - Pipeline by GC Pharma, H2 2019
Hypoparathyroidism - Pipeline by Sigilon Therapeutics Inc, H2 2019
Hypoparathyroidism - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019
Hypoparathyroidism - Dormant Projects, H2 2019

List of Figures
Number of Products under Development for Hypoparathyroidism, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Targets, H2 2019
Number of Products by Stage and Targets, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Aerami Therapeutics
  • Alize Pharma III SAS
  • Ascendis Pharma A/S
  • Chugai Pharmaceutical Co Ltd
  • Eli Lilly and Co
  • Entera Bio Ltd
  • Extend Biosciences Inc
  • GC Pharma
  • Sigilon Therapeutics Inc
  • Takeda Pharmaceutical Co Ltd
Note: Product cover images may vary from those shown
Adroll
adroll